Advances in oncology have improved treatment options, but their benefits remain out of reach for many patients who cannot afford to complete the prescribed course. This is despite the recent decision to cap trade margins on 137 identified non-scheduled anti-cancer medicines, providing some relief, writes Afshan Yasmeen...
Advances in oncology have improved treatment options, but their benefits remain out of reach for many patients who cannot afford to complete the prescribed course. This is despite the recent decision to cap trade margins on 137 identified non-scheduled anti-cancer medicines, providing some relief, writes Afshan Yasmeen...
<iframe src="https://hindustansphere.com/embed/cluster/364a14ef4c1f7f14f2521cbbb9f616717815bdb8" width="100%" height="320" style="border:0;max-width:680px" loading="lazy" title="Cancer care: Long battle for affordable treatment"></iframe>
Advances in oncology have improved treatment options, but their benefits remain out of reach for many patients who cannot afford to complete the prescribed course. This is despite the recent decision to cap trade margins on 137 identified non-scheduled anti-cancer medicines, providing some relief, writes Afshan Yasmeen...
Advances in oncology have improved treatment options, but their benefits remain out of reach for many patients who cannot afford to complete the prescribed course. This is despite the recent decision to cap trade margins on 137 identified non-scheduled anti-cancer medicines, providing some relief, writes Afshan Yasmeen...
